Stock Traders Purchase Large Volume of Call Options on Alto Neuroscience (NYSE:ANRO)

Alto Neuroscience, Inc. (NYSE:ANRO) saw some unusual options trading activity on Wednesday. Stock investors bought 2,129 call options on the stock. This is an increase of approximately 21% compared to the typical volume of 1,755 call options.

Analysts Set New Price Targets

ANRO has been the subject of several recent analyst reports. Wedbush cut shares of Alto Neuroscience from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $29.00 to $4.00 in a research note on Wednesday. Rodman & Renshaw lowered shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a research report on Wednesday. William Blair reiterated an “outperform” rating on shares of Alto Neuroscience in a research report on Tuesday, September 10th. Robert W. Baird dropped their target price on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating for the company in a research report on Wednesday. Finally, RODMAN&RENSHAW lowered shares of Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. Three analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, Alto Neuroscience presently has an average rating of “Moderate Buy” and a consensus target price of $24.40.

Alto Neuroscience Stock Down 5.3 %

Shares of ANRO opened at $4.13 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 19.85 and a current ratio of 19.85. Alto Neuroscience has a fifty-two week low of $4.04 and a fifty-two week high of $24.00. The firm has a 50 day moving average price of $12.12 and a 200-day moving average price of $12.43.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.07. As a group, research analysts forecast that Alto Neuroscience will post -2.63 earnings per share for the current year.

Institutional Investors Weigh In On Alto Neuroscience

A number of hedge funds have recently made changes to their positions in ANRO. University of Texas Texas AM Investment Managment Co. bought a new stake in shares of Alto Neuroscience in the 1st quarter worth approximately $340,000. Jennison Associates LLC bought a new stake in Alto Neuroscience during the 1st quarter valued at $7,039,000. Vanguard Group Inc. bought a new stake in Alto Neuroscience during the 1st quarter valued at $8,233,000. Price T Rowe Associates Inc. MD bought a new stake in Alto Neuroscience during the 1st quarter valued at $9,788,000. Finally, AWM Investment Company Inc. bought a new stake in Alto Neuroscience during the 1st quarter valued at $4,592,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.